Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33085408&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
StatPearls-/-? 2025[Jan]; ? (?): ? PMID33085408show ga
Remdesivir is a broad-spectrum antiviral agent that has showcased its efficacy against a spectrum of viruses, including filoviruses (eg, Ebola, Marburg), coronaviruses (eg, SARS-CoV, MERS-CoV, SARS-CoV-2), paramyxoviruses (eg, parainfluenza type III, Nipah, Hendra, measles, mumps), and Pnemoviridae (eg, respiratory syncytial virus). In vitro studies have demonstrated its antiviral activity against SARS-CoV-2, prompting its consideration as an investigational drug early in the pandemic. Following randomized clinical trials affirming superior clinical efficacy compared to placebo, remdesivir was the first antiviral drug approved by the US Food and Drug Administration (FDA). This approval signifies its role in the clinical management of patients with severe suspected or laboratory-confirmed COVID-19. This activity meticulously explores remdesivir's pharmacology, dosing, indications, contraindications, and potential adverse events to enhance patient outcomes.
StatPearls-/-? 2025 ; ? (?): ?
